Tag: Paul Marquardt
Firms act on Hengrui-GSK USD12.5bn drug development deal
Jiangsu Hengrui and GSK reached a USD12.5bn deal, with Cooley, Davis Polk and Han Kun advising
Trio acts on Nippon Paint’s USD2.3bn chemical deal
Davis Polk, Gibson Dunn, and Katzke & Morgenbesser advise on Nippon Paint’s $2.3B acquisition of AOC, owned by Lone Star Funds
Davis Polk, Appleby and Latham & Watkins act on USD23bn SPAC merger
Davis Polk, Appleby and Latham & Watkins advised on a proposed special purpose acquisition company (SPAC) merger involving Vietnamese electric vehicle manufacturer VinFast at an equity value of USD23 billion
